PMID- 24793939
OWN - NLM
STAT- MEDLINE
DCOM- 20141124
LR  - 20161125
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 32
IP  - 27
DP  - 2014 Jun 5
TI  - Risk factors associated with immunoprophylaxis failure against mother to child 
      transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan 
      province, China.
PG  - 3362-6
LID - S0264-410X(14)00583-0 [pii]
LID - 10.1016/j.vaccine.2014.04.045 [doi]
AB  - OBJECTIVE: To explore the risk factors associated with immunoprophylaxis failure 
      against mother to child transmission of hepatitis B virus (HBV) and hepatitis B 
      vaccination status in Yunnan province, China. METHODS: Multicenter cluster 
      sampling was used to select pregnant women who were positive for hepatitis B 
      surface antigen (HBsAg). HBV immunoprophylaxis was carried out for the newborns. 
      Blood samples were collected and tested for HBV markers from 7 to 10 month old 
      infants. The factors were analyzed by univariate and logistic regression. 
      RESULTS: A total of 2765 mothers and their infants were enrolled. The failure 
      rate of prevention of mother to child transmission (PMTCT) was 4.12%. The rate of 
      timely HepB1 vaccination within 24h was 98.04%, the rate of three-dose 
      vaccination was 92.30% and the rate of hepatitis B immune globulin (HBIG) 
      administration was 68.97%. Place of residence, maternal education, gestational 
      age and birth weight were related to administration of HBV immunoprophylaxis. It 
      was remarkable that the rate of HBIG administration of infants was only 63.89% 
      with whose mothers were both HBsAg and hepatitis B e antigen (HBeAg)-positive. 
      Further analysis showed that there were three risk factors associated with HBV 
      immunoprophylaxis failure: mothers who were positive for HBsAg and HBeAg, 
      maternal HBVDNA level, and HBIG administration or not. CONCLUSIONS: PMTCT of HBV 
      was well implemented in Yunnan. However, in order to achieve optimal prevention 
      of vertical HBV transmission, it is mandatory to make additional efforts to 
      improve the implementation of regulatory HBV immunoprophylaxis, especially for 
      HBsAg-positive pregnant women.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Kang, Wenyu
AU  - Kang W
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Ding, Zhengrong
AU  - Ding Z
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Shen, Liping
AU  - Shen L
AD  - National Institute for Viral Disease Control and Prevention, Chinese Center for 
      Disease Control and Prevention, Beijing 102206, China. Electronic address: 
      slpss128@126.com.
FAU - Zhao, Zhixian
AU  - Zhao Z
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Huang, Guofei
AU  - Huang G
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Xiong, Qing
AU  - Xiong Q
AD  - Center for Disease Control and Prevention of Yunnan Province, Kunming 650022, 
      China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - National Institute for Viral Disease Control and Prevention, Chinese Center for 
      Disease Control and Prevention, Beijing 102206, China.
FAU - Zhang, Shuo
AU  - Zhang S
AD  - National Institute for Viral Disease Control and Prevention, Chinese Center for 
      Disease Control and Prevention, Beijing 102206, China.
FAU - Wang, Feng
AU  - Wang F
AD  - National Institute for Viral Disease Control and Prevention, Chinese Center for 
      Disease Control and Prevention, Beijing 102206, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20140429
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (DNA, Viral)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Immunoglobulins)
RN  - XII270YC6M (hepatitis B hyperimmune globulin)
SB  - IM
MH  - China/epidemiology
MH  - DNA, Viral/blood
MH  - Female
MH  - Hepatitis B/*prevention & control
MH  - Hepatitis B Surface Antigens/blood
MH  - Hepatitis B Vaccines/*therapeutic use
MH  - Hepatitis B e Antigens/blood
MH  - Humans
MH  - Immunoglobulins/therapeutic use
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*epidemiology
MH  - Risk Factors
OTO - NOTNLM
OT  - Hepatitis B virus
OT  - Immunoprophylaxis
OT  - Mother-to-child transmission
OT  - Risk factor
EDAT- 2014/05/06 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/05/06 06:00
PHST- 2013/10/19 00:00 [received]
PHST- 2014/04/09 00:00 [revised]
PHST- 2014/04/17 00:00 [accepted]
PHST- 2014/05/06 06:00 [entrez]
PHST- 2014/05/06 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S0264-410X(14)00583-0 [pii]
AID - 10.1016/j.vaccine.2014.04.045 [doi]
PST - ppublish
SO  - Vaccine. 2014 Jun 5;32(27):3362-6. doi: 10.1016/j.vaccine.2014.04.045. Epub 2014 
      Apr 29.